Dexamethasone in Hospitalized Patients with Covid-19
RECOVERY
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower
28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory Support.
Remdesivir for the Treatment of Covid-19
ACTT-1
Among patients with Covid-19 hospitalized with lower respiratory tract involvement, remdesivir reduced the median time to recovery by approximately four days.
There was no difference in 14-day survival between remdesivir and placebo groups. The report of 28-day mortality is pending.
Solidarity (WHO)
No benefit
Baricitinib
ACTT-2
Remdesivir, Baricitinib Janus kinase (JAK) inhibitor
Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation.
Hydroxychloroquine (HCQ)
RECOVERY
No benefit